article thumbnail

Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly’s connected insulin solutions

The Pharma Data

and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Lilly will commercialize the pen platform, which will include the new app and Lilly’s connected insulin pen solutions.

Insulin 40
article thumbnail

Velocity Investigators Active at the American Diabetes Association (ADA) 83rd Scientific Sessions

Velocity Clinical Research

Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A

Insulin 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Provention faces delay in FDA review of diabetes prevention antibody

pharmaphorum

Provention licensed rights to teplizumab from MacroGenics in 2010, eight years after former licensee Lilly abandoned the drug in the wake of a failed phase 3 trial looking at its role in treating newly-diagnosed T1D patients. Photo by Dennis Klicker on Unsplash.

article thumbnail

WHO announces international hub for mRNA vaccine training

pharmaphorum

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . Long-term progress.

article thumbnail

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

Crucially, biosimilars manufacturers must also demonstrate that their product’s safety and efficacy profile won’t go down if a patient switches back and forth between the biosimilar and the reference product during the course of treatment. Because most biologics are mixtures of variants, they really can’t be copied exactly.”.

article thumbnail

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. Novo Nordisk, the pharmaceutical manufacturer of Ozempic and Wegovy, is actively addressing these supply challenges. The approved drugs contain the base form of semaglutide.

article thumbnail

Six collaborations driving drug discovery innovation

Drug Discovery World

OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of foetal growth and development, and its binding protein, IGFBP-3. Perspective will also acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey.

Drugs 59